Journal of Dermatological Treatment最新文献_第8页

Cardiometabolic multimorbidity is common among patients with psoriasis and is associated with poorer outcomes compared to those without comorbidity. 心脏代谢多病在牛皮癣患者中很常见，与无合并症的患者相比，其预后较差。

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2022-11-01 Epub Date: 2022-07-06 DOI: 10.1080/09546634.2022.2089329

Clinton W Enos, Vanessa L Ramos, Robert R McLean, Tin-Chi Lin, Nicole Foster, Blessing Dube, Abby S Van Voorhees

{"title":"Cardiometabolic multimorbidity is common among patients with psoriasis and is associated with poorer outcomes compared to those without comorbidity.","authors":"Clinton W Enos, Vanessa L Ramos, Robert R McLean, Tin-Chi Lin, Nicole Foster, Blessing Dube, Abby S Van Voorhees","doi":"10.1080/09546634.2022.2089329","DOIUrl":"https://doi.org/10.1080/09546634.2022.2089329","url":null,"abstract":"Background: Associations between cardiometabolic multimorbidity and response to therapy in psoriasis are unknown.Objective: Determine the associations of multimorbidity with response to biologic treatment in psoriasis patients.Methods: CorEvitas Psoriasis Registry participants who initiated biologic therapy and had 6-month follow-up were stratified by 0, 1, 2+ comorbidities (diabetes, hypertension, hyperlipidemia). Adjusted odds ratios (95% CIs) were calculated overall and separately by biologic class (TNFi, IL-17i, IL-12/23i + IL-23i), to assess the likelihood of achieving response for the 1 and 2+ groups vs. 0.Results: Of 2,923 patients, 49.5%, 24.7% and 25.8% reported 0, 1 and 2+ comorbidities, respectively. Overall, likelihood of PASI75 was 18% (OR = 0.82; 95%CI: 0.67, 1.00) and 23% (OR = 0.77; 95%CI: 0.63, 0.96) lower in those with 1 and 2+ comorbidities, respectively, vs. 0. In those who initiated IL-17i, odds of PASI75 and PAS90 were 34% (OR = 0.66; 95%CI: 0.48-0.91) and 35% (OR = 0.65; 95%CI: 0.47-0.91) lower in the 2+ multimorbidity cohort. No significant associations were found among users of TNFi or IL-12/23i + IL-23i groups in the multimorbidity group.Limitations: Patients may not be representative of all psoriasis patients.Conclusion: Multimorbidity in psoriasis may decrease the likelihood of achieving treatment response to biologic therapy and should be considered when discussing treatment expectations with patients.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":" ","pages":"2975-2982"},"PeriodicalIF":2.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40326152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Efficacy and safety of oral methotrexate versus oral mini pulse betamethasone therapy in the treatment of lichen planus: a comparative study. 口服甲氨蝶呤与口服小脉冲倍他米松治疗扁平苔藓的疗效和安全性比较研究。

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2022-11-01 Epub Date: 2022-07-31 DOI: 10.1080/09546634.2022.2104446

Nour Alhuda Gamal Alsakaan, Sherief Abd-Elsalam, Mohamed M Fawzy, Nagwa Mohammad Elwan

{"title":"Efficacy and safety of oral methotrexate versus oral mini pulse betamethasone therapy in the treatment of lichen planus: a comparative study.","authors":"Nour Alhuda Gamal Alsakaan, Sherief Abd-Elsalam, Mohamed M Fawzy, Nagwa Mohammad Elwan","doi":"10.1080/09546634.2022.2104446","DOIUrl":"https://doi.org/10.1080/09546634.2022.2104446","url":null,"abstract":"Background: Lichen planus (LP) is a chronic inflammatory mucocutaneous disease. Systemic corticosteroids are the treatment of choice for generalized LP but their use is limited due to side effects. Oral mini pulse (OMP) therapy represents a good alternative. Also, Methotrexate (MTX) can be used as an alternative and safe modality in LP.Objectives: To compare the efficacy and safety of oral MTX versus OMP betamethasone in the treatment of different types of LP.Patients and method: The study included 40 patients presenting with LP who were randomly divided into two groups. Group A for oral MTX 7.5 mg weekly & group B for OMP betamethasone 3 mg weekly for a maximum of 12 weeks. Basic laboratory investigations were done on both groups. Follow-up investigations were done on the 2nd, 4th, 8th and 12th weeks. The percentage of improvement in each patient was calculated on a scale according to the appearance of new lesions, degree of pruritus/pain, subsidence of cutaneous lesions and clearance of the oral lesion.Results: In the MTX group, 55% of patients showed excellent improvement, 25% showed good improvement and 20% showed partial improvement. In the OMP group, 85% of patients showed excellent improvement, 10% showed good improvement and 5% showed partial improvement. The reported clinical and laboratory adverse effects were tolerable and didn't lead to the discontinuation of treatment.Conclusion: OMP betamethasone and low dose MTX may be considered effective and safe lines of treatment for different types of LP and may represent good and safe alternative options for conventional daily corticosteroid therapy.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":" ","pages":"3039-3046"},"PeriodicalIF":2.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40522573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Complementary and alternative treatment methods practiced by parents in pediatric cases diagnosed with atopic dermatitis. 在诊断为特应性皮炎的儿童病例中，父母采用的补充和替代治疗方法。

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2022-11-01 Epub Date: 2022-07-12 DOI: 10.1080/09546634.2022.2097159

Ayşe Akbaş, Zeynep Şengül Emeksiz, Ahu Yorulmaz, Yıldız Hayran, Fadime Kılınç, Halil Ibrahim Yakut, Müge Toyran, Kezban İpek Demir

{"title":"Complementary and alternative treatment methods practiced by parents in pediatric cases diagnosed with atopic dermatitis.","authors":"Ayşe Akbaş, Zeynep Şengül Emeksiz, Ahu Yorulmaz, Yıldız Hayran, Fadime Kılınç, Halil Ibrahim Yakut, Müge Toyran, Kezban İpek Demir","doi":"10.1080/09546634.2022.2097159","DOIUrl":"https://doi.org/10.1080/09546634.2022.2097159","url":null,"abstract":"Introduction: Atopic dermatitis (AD) is a chronic, recurrent, and inflammatory skin disease experienced mostly in childhood. Chronicity of the disease, relapses, constant need of regular skin care causes seeking for alternative treatments.Aim: The aim of this study is to evaluate the complementary and alternative treatments (CAT) used by parents' caregivers in pediatric patients diagnosed with AD, and the association between CAT use and patient characteristics.Materials and methods: A questionnaire questioning the sociocultural and demographic characteristics of the family, the clinical findings of the patients, their treatments and CAT applications was recorded.Results: Eighty-three patients were included in the study. 68.7% of the patients used at least one type of CAT. Vitamins and oils were the most commonly used CAT (48.8% and 47%, respectively) and 73.3% of the patients using CAT continued normal AD treatment while using CAT. The biggest factor affecting CAT choice was the advice of the immediate circle (75%), and 40.6% of the patients stated that they benefited from the complementary therapy.Conclusions: CAT are widely used in AD. Physicians should know the socio-cultural structure of the region they are in, the CAT used and their side effects, and inform the families.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":" ","pages":"3014-3021"},"PeriodicalIF":2.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40463101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Creating room for innovation in the treatment of psoriasis. 为银屑病治疗创造创新空间。

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2022-11-01 DOI: 10.1080/09546634.2022.2138396

Peter C M van de Kerkhof

引用次数: 0

Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders. 斑块型银屑病患者从乌斯特金单抗或阿达木单抗切换到瑞尚单抗可改善次优应答者的PASI和DLQI结果。

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2022-11-01 DOI: 10.1080/09546634.2022.2095328

Bruce Strober, April Armstrong, Simone Rubant, Manish Patel, Tianshuang Wu, Huzefa Photowala, Jeffrey Crowley

{"title":"Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders.","authors":"Bruce Strober, April Armstrong, Simone Rubant, Manish Patel, Tianshuang Wu, Huzefa Photowala, Jeffrey Crowley","doi":"10.1080/09546634.2022.2095328","DOIUrl":"https://doi.org/10.1080/09546634.2022.2095328","url":null,"abstract":"Background: Psoriasis is often treated with biologic therapies. While many patients see improvement in their symptoms with treatment, some achieve only partial success.Objective and methods: In this post-hoc analysis we assess Psoriasis Area Severity Index (PASI) and Dermatology Life Quality Index (DLQI) results from patients who switched to RZB due to suboptimal results that originally received ADA (N = 53, IMMvent NCT02694523) or UST (N = 172, UltIMMa-1 [NCT02684370], UltIMMa-2 [NCT02684357]).Results: For patients originally treated with ADA, after three doses of RZB, 83.3% of PASI 50 to <75 patients improved to PASI ≥75 and for PASI 75 to <90 patients, 77.1% improved to PASI ≥90. For patients originally treated with UST, after 7 doses of RZB, 86.8% of PASI <75 patients improved to PASI ≥75 and 75.5% of PASI 75 to ≤90 patients improved to PASI ≥90. No patients demonstrated worsening from their initial PASI group after switching. There were no significant safety events associated with switching patients to RZB without a washout period.Conclusion: For patients with an inadequate or incomplete response to UST or ADA, switching to RZB improved PASI scores and DLQI for patients with moderate to severe plaque psoriasis with no significant safety risks.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"33 7","pages":"2991-2996"},"PeriodicalIF":2.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10758533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia. 口服米诺地尔、非那雄胺和度他雄胺治疗雄激素性脱发的比较。

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2022-11-01 Epub Date: 2022-08-15 DOI: 10.1080/09546634.2022.2109567

Aditya K Gupta, Mesbah Talukder, Greg Williams

{"title":"Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia.","authors":"Aditya K Gupta, Mesbah Talukder, Greg Williams","doi":"10.1080/09546634.2022.2109567","DOIUrl":"https://doi.org/10.1080/09546634.2022.2109567","url":null,"abstract":"Background: Androgenetic alopecia (AGA) is the most common cause of hair loss, often challenging to treat. While oral finasteride (1 mg/d) is an FDA-approved treatment for male AGA, oral minoxidil and oral dutasteride are not approved yet. However, clinicians have been increasingly using these two drugs off-label for hair loss. Recently, Japan and South Korea have approved oral dutasteride (0.5 mg/d) for male AGA.Efficacy and safety: A probable efficacy ranking, in decreasing order, is - dutasteride 0.5 mg/d, finasteride 5 mg/d, minoxidil 5 mg/d, finasteride 1 mg/d, followed by minoxidil 0.25 mg/d. Oral minoxidil predominantly causes hypertrichosis and cardiovascular system (CVS) symptoms/signs in a dose-dependent manner, whereas oral finasteride and dutasteride are associated with sexual dysfunction and neuropsychiatric side effects.Pharmacokinetics and pharmacodynamics: The average plasma half-lives of minoxidil, finasteride, and dutasteride are ∼4 h, ∼4.5 h, and ∼5 weeks, respectively. Minoxidil acts through multiple pathways to promote hair growth. It has been shown as a vasodilator, an anti-inflammatory agent, a Wnt/β-catenin signaling inducer, and an antiandrogen. Finasteride inhibits 5α-reductase (5AR) type II isoenzyme, while dutasteride inhibits both type I and type II. Thus, dutasteride suppresses DHT levels more than finasteride in the serum and scalp.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":" ","pages":"2946-2962"},"PeriodicalIF":2.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40596568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 18

Dupilumab for the treatment of adult atopic dermatitis in special populations. Dupilumab用于治疗特殊人群的成人特应性皮炎。

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2022-11-01 Epub Date: 2022-07-19 DOI: 10.1080/09546634.2022.2102121

Cataldo Patruno, Luca Potestio, Massimiliano Scalvenzi, Teresa Battista, Flavia Raia, Vincenzo Picone, Gabriella Fabbrocini, Maddalena Napolitano

{"title":"Dupilumab for the treatment of adult atopic dermatitis in special populations.","authors":"Cataldo Patruno, Luca Potestio, Massimiliano Scalvenzi, Teresa Battista, Flavia Raia, Vincenzo Picone, Gabriella Fabbrocini, Maddalena Napolitano","doi":"10.1080/09546634.2022.2102121","DOIUrl":"https://doi.org/10.1080/09546634.2022.2102121","url":null,"abstract":"Background: Special populations (SPs) involve people who require additional consideration in clinical research. Effectiveness of treatment or occurrence of side effects may be different in SPs with respect to not-SPs.Objectives: To retrospectively compare the effectiveness and safety of dupilumab in AD treatment of SPs versus not-SPs.Methods: A 52-weeks retrospective study was performed enrolling patients with a diagnosis of moderate-to-severe AD undergoing treatment with dupilumab at labeled dosage. Patients were divided in Group A (SPs patients) and Group B (not-SPs patients). Disease severity was assessed using Eczema Area Severity Index (EASI), Pruritus-Numerical Rating Scale (P-NRS), and Dermatology Life Quality Index (DLQI) score at baseline and after 4 weeks (W4), W16, W24, and W52.Results: A total of 263 patients were enrolled and divided in Group A (25) and Group B (238). SPs included history of cancer, severe kidney failure, viral hepatitis, neurological diseases, acquired immunodeficiency syndrome, and transplanted patients. A statistically significant reduction of EASI, DLQI, and P-NRS was assessed in both groups at each follow-up visit (p < .0001), without significant differences between the groups. No differences were recorded for safety.Conclusions: There are not significant differences between SPs and not-SPs as regards effectiveness and safety of dupilumab in AD management.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":" ","pages":"3028-3033"},"PeriodicalIF":2.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40599784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16

Age-based treatment differences in and reluctance to treating older adults with systemic antipsoriatic therapy - a mixed-method pilot study. 基于年龄的治疗差异和老年人不愿接受全身抗银屑病治疗——一项混合方法的试点研究。

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2022-11-01 Epub Date: 2022-06-28 DOI: 10.1080/09546634.2022.2089330

Elke L M Ter Haar, Marcia Tummers, Ewald M Bronkhorst, Peter C M van de Kerkhof, Elke M G J de Jong, Satish F K Lubeek

{"title":"Age-based treatment differences in and reluctance to treating older adults with systemic antipsoriatic therapy - a mixed-method pilot study.","authors":"Elke L M Ter Haar, Marcia Tummers, Ewald M Bronkhorst, Peter C M van de Kerkhof, Elke M G J de Jong, Satish F K Lubeek","doi":"10.1080/09546634.2022.2089330","DOIUrl":"https://doi.org/10.1080/09546634.2022.2089330","url":null,"abstract":"Background: Evidence-based guidance in older adults (≥65 years) with psoriasis is sparse and undertreatment might be present.Objectives: To assess prescribing patterns, comfort levels, barriers and needs of dermatologists when treating older adults with systemic antipsoriatic therapy.Methods: A mixed-methods design was used including a survey among all Dutch dermatologists and residents, followed by semi-structured interviews.Results: Most of the survey respondents applied systemic treatment to the same extent in older versus younger patients (n = 49; 67.1%) and weren't reluctant prescribing systemic therapy (n = 50; 68.5%) in older adults. However, 26% (n = 19) of the respondents treated older adults less often with systemic therapy compared to younger patients and 68.1% (n = 49) performed additional actions in older adults, e.g. intensified monitoring or dose reduction. Based on the survey and interviews (n = 10), the main reasons for these age-based treatment differences were comorbidity, comedication, and fear of adverse events. More evidence-based guidance, education, and time to assess older adults were identified as most important needs, especially regarding frailty screening.Conclusions: Age-based treatment differences in and reluctance to treating older adults with systemic antipsoriatic therapy were common. There is a need for more evidence-based guidance, education, and consultation time, to improve treatment in this growing population.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":" ","pages":"2983-2990"},"PeriodicalIF":2.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40407046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the potential of nanocarriers in antipsoriatic therapeutics. 探索纳米载体在抗银屑病治疗中的潜力。

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2022-11-01 Epub Date: 2022-06-21 DOI: 10.1080/09546634.2022.2089616

Mohammad Shaif, Poonam Kushwaha, Shazia Usmani, Supriya Pandey

{"title":"Exploring the potential of nanocarriers in antipsoriatic therapeutics.","authors":"Mohammad Shaif, Poonam Kushwaha, Shazia Usmani, Supriya Pandey","doi":"10.1080/09546634.2022.2089616","DOIUrl":"https://doi.org/10.1080/09546634.2022.2089616","url":null,"abstract":"Psoriasis is an autoimmune disease characterized by erythematous, scaly patches on the skin. It can be effectively managed with topical therapies since they deliver drugs to target sites of disease efficiently and can minimize systemic side-effects while ensuring high patient compliance. However, conventional topical formulations are ineffective in treating psoriasis due to their poor percutaneous penetration and inability to reach deeper layers of the skin. Thus, it is important to explore new approaches for managing psoriasis safely and effectively while also maintaining patient compliance without compromising safety. Over the last few decades, a variety of nanocarriers have been extensively investigated as a new approach to delivering drugs to the skin that are effective against psoriasis. These nanocarriers are notable for their therapeutic effectiveness, increased localization of medication in the skin, and reduced side-effects. The purpose of this review is to explore the recent advances in polymer-based, lipid-based, metallic, and microneedle-based novel nanoformulations of antipsoriatic drugs. There have been detailed discussions about several nanocarrier systems including nanoemulsions, liposomes, nanostructured lipid carriers, ethosomes, solid lipid nanoparticles, micelles, gold nanoparticles, silver nanoparticles, and microneedles. In a nutshell, nanoformulations are considered a promising avenue for psoriasis treatment since they offer better penetration, targeted delivery, and enhanced safety and efficacy.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":" ","pages":"2919-2930"},"PeriodicalIF":2.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40164389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Periocular molluscum contagiosum in an atopic dermatitis patient treated with upadacitinib. upadacitinib治疗的特应性皮炎患者的眼周传染性软疣。

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2022-11-01 Epub Date: 2022-07-25 DOI: 10.1080/09546634.2022.2104445

E De Luca, N Gori, A Chiricozzi, A Di Stefani, K Peris

引用次数: 1